

Nutrognics, Inc. Income Statement and Balance Sheet for QII 2014
covering the period April 1, 2014 through June 30, 2014.
(unaudited)

Nutrognics, Inc. has 32,820,513 common shares issued and outstanding as of 30 September 2014.

Nutrognics, Inc. is providing their QII 2014 Income Statement and Balance Sheet to conform to the OTC requirements for attaining "Limited" trading status. These are unaudited and without corresponding notes, the basis of presentation is US GAAP preparation is by a qualified third party.

INCOME STATEMENT				QIR	QIIR	YTD
	Income			694,145	1,922,450	2,616,595
	Cost of Goods Sold			<u>616,818</u>	<u>1,132,034</u>	<u>1,748,852</u>
	Gross Profit	\$		77,327	790,416	867,743
		%		11.1%	41.1%	33.2%
	Total Expense			180,741	1,027,987	1,208,728
	Net Operating Income			(103,414)	(237,571)	(340,985)
	Net Other Income			(24,775)	(361,543)	(386,318)
	NET INCOME			(128,189)	(599,114)	(727,303)

Nutrognics, Inc. Income Statement and Balance Sheet for QII 2014
covering the period April 1, 2014 through June 30, 2014.

(unaudited) cont.

Nutrognics, Inc. is providing their QII 2014 Income Statement and Balance Sheet to conform to the OTC requirements for attaining "Limited" trading status. These are unaudited and without corresponding notes, the basis of presentation is US GAAP preparation is by a qualified third party.

					Q1R	Q1R
BALANCE SHEET						
	Current Assets					
		Checking/Savings/Petty Cash			191,560	248,234
		Accounts Receivable			386,176	849,282
		Inventory			921,079	692,323
		Other Current Assets			-	18,219
	Total Current Assets				1,498,815	1,808,058
	Total Fixed Assets				99,526	1,410,685
	Total Other Assets				13,101	133,921
	Goodwill/Other Intangibles				117,824	3,431,737
TOTAL ASSETS					1,729,266	6,784,401
LIABILITIES & EQUITY						
	Liabilities					
	Current Liabilities					
		Accounts Payable			625,398	911,148
	Other Current Liabilities					
		Advances-Crestmark			244,782	423,956
		Employment-Related			17,297	17,405
		Notes Payable			5,320	518,109
		Other			145,480	294,160
	Total Other Current Liabilities				412,879	1,253,630
	Total Current Liabilities				1,038,277	2,164,778
	Total Long Term Liabilities				1,084,605	2,920,866
	Total Liabilities				2,122,882	5,085,644
	Total Equity				(393,616)	1,698,757
TOTAL LIABILITIES & EQUITY					1,729,266	6,784,401

CASH FLOW							
					QIR	QIIR	YTD
	Net Income				(128,189)	(599,114)	(727,303)
	Adjustment to Reconcile Net Income						
	to Cash Provided by Operations						
	Depreciation				12,410	12,411	24,821
	Cash Increase Due to Acquisition					71,118	71,118
	Change in Accounts Receivable				(144,318)	(54,776)	(199,094)
	Change in Inventories				189,106	275,894	465,000
	Change in Current Other Assets				(8,502)	(60,228)	(68,730)
	Change in Accounts Payable				(104,939)	(18,240)	(123,179)
	Change in Other Current Liabilities				246,031	178,625	424,656
	Net Cash Provided by Operating Activities				61,599	(194,310)	(132,711)
	Investing Activities						
	Fixed Assets				(9,155)	174,333	165,178
	Goodwill					(2,841,913)	(2,841,913)
	Investment in Subsidiaries					(889,270)	(889,270)
	Net Cash Provided/Used by Investing Activities				(9,155)	(3,556,850)	(3,566,005)
	Financing Activities						
	Net Cash Provided by Financing Activities				14,612	3,807,834	3,822,446
	Net Cash Increase or Decrease				67,056	56,674	123,730
	Cash at the Beginning of the Period				124,504	191,560	124,504
	Cash at the End of the Period				191,560	248,234	248,234

Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, David Sackler certify that:

1. I have reviewed this Qllr 2014 Quarterly Financial Statements of Nutrogonics, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

1 April 2015

David Sackler, CEO

Douglas A. Scott, Jr. CFO

_(Digital Signatures should appear as "/s/ [OFFICER NAME]")